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Background: Despite the success of genome-wide association studies for asthma, few, if any, definitively causal
variants have been identified and there is still a substantial portion of the heritability of the disease yet to be
discovered. Some of this “missing heritability” may be accounted for by family-specific coding variants found to be
segregating with asthma.
Methods: To identify family-specific variants segregating with asthma, we recruited one family from a previous
study of asthma as reporting multiple asthmatic and non-asthmatic children. We performed whole-exome
sequencing on all four children and both parents and identified coding variants segregating with asthma that were
not found in other variant databases.
Results: Ten novel variants were identified that were found in the two affected offspring and affected mother, but
absent in the unaffected father and two unaffected offspring. Of these ten, variants in three genes (PDE4DIP, CBLB,
and KALRN) were deemed of particular interest based on their functional prediction scores and previously reported
function or asthma association. We did not identify any common risk variants segregating with asthma, however,
we did observe an increase in the number of novel, nonsynonymous variants in asthma candidate genes in the
asthmatic children compared to the non-asthmatic children.
Conclusions: This is the first report applying exome sequencing to identify asthma susceptibility variants. Despite
having sequenced only one family segregating asthma, we have identified several potentially functional variants in
interesting asthma candidate genes. This will provide the basis for future work in which more families will be
sequenced to identify variants across families that cluster within genes.
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The genome-wide association approach to uncovering the
genetic factors influencing common phenotypes is pre-
mised on the “common disease, common variant” hypoth-
esis in which alleles that are common in the population
(minor allele frequency [MAF] > 1%) will be associated with
these phenotypes. At least twelve genome-wide association
studies (GWAS) of asthma have been conducted and have
yielded numerous associations, with the most significant
(and in most cases replicated) associations occurring in or
near the following genes: ORMDL3 [1,2], PDE4D [3], HLA-* Correspondence: andrew.dewan@yale.edu
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reproduction in any medium, provided the orDRB1 [2], HLA-DQ [2,4], RAD50-IL13 [4], DENND1B [5],
TLE4 [6], SMAD3 [2], IL1RL1 [7], IL18R1 [2], IL33 [2],
IL2RB [2], RORA [2], and SLC22A5 [2]. These findings have
greatly expanded our understanding of the disease, having
identified several novel genetic loci that had never previ-
ously been implicated in the pathogenesis of asthma (e.g.
ORMDL3, RAD50, DENND1B, TLE4). Despite these suc-
cesses, no definitive causal variants have been identified in
any of these genes. It is asserted that the associated variants
are in LD with the causal variants in these genes, but more
effort must be made to identify causal variants so that we
can begin to understand the biology of these genes in the
etiology of asthma.
It is now recognized that GWAS are not able to iden-
tify all or even the majority of the genetic variantsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tion of the heritability of a phenotype not explained by
known genetic variants has been termed the “missing
heritability.” AMD is so far the disease with the highest
proportion of heritability explained by known loci, but
even then only explains ~50% of the heritability [11].
Large sample sizes have allowed us to identify loci with
small effect sizes yielding p-values well below the typical
5 × 10-8, required for a scan of one million single-
nucleotide polymorphisms (SNPs), but we are no longer
identifying major contributors to phenotype variation. In
the case of height, across two studies, a total of 60,000
subjects were genotyped, but significantly associated,
and replicated, variants in two different genes only
explained between 0.3 and 0.5% of the variation [12,13].
For asthma, the population attributable fraction esti-
mates for known asthma loci range from 3.9 to 24%
[14], while explaining more risk than typical height loci,
still indicate a substantial proportion of missing herit-
ability. This suggests that a paradigm shift in our search
for susceptibility loci for common diseases is warranted.
One explanation for the lack of functional variant
identification is that the degree of genetic heterogeneity
for common diseases is markedly higher than previously
thought, possibly due to the presence of rare or even
family-specific mutations with a large effect [15]. Our
hypothesis is that individual families segregate “family-
specific” variants contributing to asthma susceptibility
and that at least one family-specific variant is necessary
but not sufficient for disease development within indivi-
duals in the family. It is when these family-specific
mutations occur in the context of common asthma sus-
ceptibility variants that the disease will develop.
To identify family-specific variants segregating with
asthma, we recruited one family originally identified via
one asthmatic child enrolled in the Perinatal Risk of
Asthma in Infants of Asthmatic Mothers (PRAM) study
[16] as reporting multiple asthmatic and non-asthmatic
children. We performed whole-exome sequencing on all
four children and both parents.
Methods
Patient recruitment/sample collection
The recruitment, questionnaire, blood collection and
exome sequencing were approved by the Yale University
Human Investigation Committee. The family was identi-
fied from information collected as part of the Perinatal
Risk of Asthma in Infants of Asthmatic Mothers
(PRAM), a study designed to assess the risk of asthma in
children born to asthmatic mothers. We identified one
family in this study that originally reported having two
asthmatic children and two non-asthmatic children. The
family was recontacted by a research associate to explain
the study and determine the family’s interest inparticipating. A trained interviewer and phlebotomist
visited the family in their home to conduct the interview
and collect blood samples from each family member.
The phlebotomist drew 10mL of blood from each family
member in purple top EDTA tubes. The phlebotomist
stored the blood on ice and delivered it to the lab within
24 hours. Each blood sample was divided into 1mL ali-
quots. DNA was extracted from one 1mL aliquot using
the QIAGEN Blood Maxi kit. Each DNA sample was
run on a 1% agarose gel to determine if it was of high
quality (strong high molecular weight [> 10kb] band and
no smear). DNA was quantified using TaqMan RNase P
Detection Reagent Kit (Applied Biosystems).
Phenotype collection
The interviewer conducted an interview with each family
member to assess their asthma diagnosis, symptoms and
medication. For each subject, the interviewer asked
questions about their asthma and/or allergies. The sub-
ject was asked about asthma diagnosis by a physician,
date of diagnosis and name of physician. Whether or not
they had been diagnosed, the subject was asked about
any of the following symptoms: wheeze, persistent
cough, chest tightness or shortness of breath. A detailed
description of the frequency and duration of symptoms
for the past 12 months was obtained. If the subject had
not experienced symptoms in the past 12 months, then
the dates when symptoms last occurred, and a descrip-
tion of their frequency and duration at that time was
recorded. The interviewer recorded all asthma medica-
tions used in the past 12 months; route of administra-
tion (nebulizer, inhaler, oral) and frequency of use. If no
medication had been used in the past year, the date
medication was last used, name of the medication and
frequency of use were ascertained. Questions were asked
about the occurrence and frequency of upper respiratory
infections in the past 12 months, and life-time lower re-
spiratory infections, particularly: respiratory syncytial
virus (RSV), bronchitis, bronchiolitis, pneumonia and
croup. Information was gathered about hospitalizations
and emergency room visits for asthma, and other re-
spiratory illnesses. Physician visits in the past 12 months
and treatment by a pulmonologist, allergist or asthma
specialist were recorded. Questions were asked to deter-
mine whether their physical activity is limited by asthma,
or asthma symptoms. For children, the home interview
also obtained information on post-natal risk factors for
asthma development (e.g. newborn intensive care nur-
sery stays).
Sequencing
Five micrograms of DNA was submitted to the Yale
Center for Genome Analysis. One microgram of gen-
omic DNA was sheared to a mean fragment length of
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E210, part #5000003). Fragmented DNA samples were
then transferred to a 96-well plate and library construc-
tion was completed using a liquid handling robot (Cali-
per Sciclone, part #SG3-11020-0100). Magnetic AMPure
XP beads (Beckman Coulter, part #63882) were used to
purify the sheared DNA samples and remained with the
sample throughout library construction. Following each
process step, DNA was selectively precipitated by weight
and re-bound to the beads through addition of a 20%
polyethylene glycol, 2.5 M NaCl solution. Following frag-
mentation, T4 DNA polymerase and T4 polynucleotide
kinase blunt ended and phosphorylated the fragments.
The large Klenow fragment then added a single adenine
residue to the 3' end of each fragment and custom
adapters (IDT) were ligated using T4 DNA ligase.
Adapter-ligated DNA fragments were then amplified via
the polymerase chain reaction (PCR) using custom-
made primers (IDT). During PCR, a unique 6 base index
was inserted at one end of each DNA fragment. Sample
concentration and insert size distribution were deter-
mined using the Caliper LabChip GX system (Caliper,
part #122000/B). Samples yielding at least 1 μg of ampli-
fied DNA were used for capture.
Five hundred nanograms of prepared genomic DNA
library was lyophilized with Cot-1 DNA and custom
adapter blocking oligos (IDT). The dried sample was
reconstituted according the manufacturer's protocol
(Roche/Nimblegen), heat-denatured, and mixed with bio-
tinylated DNA probes produced by Nimblegen (Nimble-
gen, SeqCap EZ Exome version 2, part #05860504001).
Hybridizations were performed at 47°C for 68 hours. Once
the capture was complete the samples were mixed with
streptavidin-coated beads and washed with a series of
stringent buffers to remove non-specifically bound DNA
fragments. The captured fragments were PCR amplified
and purified with AMPure XP beads. Capture efficiency
was evaluated by quantitative PCR (Roche Light Cycler
480, part #5015243001). Equal amounts of pre- and post-
capture libraries were evaluated at 4 sites to confirm suc-
cessful exome enrichment and at 2 other sites to show
non-exome de-enrichment in the captured sample relative
to the pre-capture library. All samples met appropriate
cut-offs for both and were quantified by qRT-PCR using a
commercially available kit (KAPA Biosystems, part
#KK4601). Insert size distribution was determined with
the LabChip GX.
Sample concentrations were normalized to 2 nM,
combined accordingly for the number of samples to be
sequenced per lane, and loaded onto Illumina version 3
flow cells at a concentration that yields 170–200 million
passing filter clusters. The samples were sequenced
using 75bp paired-end sequencing on an Illumina HiSeq
2000 according to Illumina protocols. The 6 base pairindex was read during an independent sequencing read
that automatically follows the completion of read 1 and
uses an additional sequencing primer (Illumina, part
#15019606).
Signal intensities were converted to individual base
calls on the machine during a run using the system's Real
Time Analysis (RTA) software. Sample de-multiplexing
was performed using Illumina's CASAVA 1.8 software
suite and FASTQ files for each sample were produced.
Alignment, variant identification and filtering
Reads were aligned using the Burrows-Wheeler Algo-
rithm (BWA) [17] to the reference human genome
(build 37). Alignments for each sample were converted
to BAM format, sorted, indexed, PCR duplicates marked
and then merged into one BAM file for all six sample
using Samtools [18]. Alignments in the the combined
BAM file were then locally realigned around inser-
tions/deletions (indels), recalibrated, and variants called
(SNPs and indels using the UnifiedGenotyper) for the
all six samples together using the utilities in the Ge-
nome Analysis Toolkit (GATK) [19,20].
Variants were filtered and flagged as low quality using
the following metrics: three or more variants detected
within 10bp; four or more alignments map to different
locations equally well; coverage less than five reads;
quality score < 50; low quality for a particular sequence
depth (variant confidence/unfiltered depth < 1.5); and
strand bias (Phred-scaled p-values using Fisher’s Exact
Test > 200). A variant flagged for any ONE of these fil-
ters was labeled ‘low quality’ and not considered further
in this analysis.
Annotation
Variants were annotated using ANNOVAR [21] for func-
tion (exonic or splicing); gene; exon function (synonymous,
nonsynonymous, stopgain, nonframeshift or frameshift
indel); amino acid change; conservation; allele frequency in
1000 Genomes Project; dbSNP reference number; func-
tional prediction scores (SIFT [prediction of a change
being damaging (> 0.95) or tolerated (< 0.95)], Polyphen2
[prediction if a change is damaging (> 0.85), possibly dam-
aging (0.85-0.15) or benign (< 0.15)], LRT [likelihood ratio
test for codon constraint ranging from 0–1 with larger
scores indicating constrained], MutationTaster [prediction
of a disease causing variant, 1-pvalue], PhyloP [prediction
of a conserved (> 0.95) or non-conserved (< 0.95) site])
[22]; and chromosome position.
Validation genotyping
To validate the genotypes of the variants in PDE4DIP,
CBLB and KALRN we designed a custom TaqMan assay
(Applied Biosystems) targeting each of these variants.
Each sample was run in triplicate. Fourteen additional
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as negative controls as they were only expected to be
homozygous wild-type.Candidate gene variant counts
We previously identified 251 asthma candidate genes
from the literature [23]. We queried the list of 38,103
variants that passed the QC filters to identify those var-
iants that were annotated as being within or near one of
these genes. For each subject, we counted the number of
non-referent alleles at each variant annotated within one
of the 251 genes. We then restricted this to only novel
variants (not contained within dbSNP). Finally, we
restricted this to novel and non-synonymous variants. In
order to compute the statistical significance of the num-
ber of novel or novel and nonsynonymous variants
among the case children compared to control, we used
the Pearson χ2 test and also calculated odds ratios (OR)
and 95% confidence intervals (95%CI). We compared
the total number of novel rare alleles (n=16 among
cases, n=8 among controls) to the total number of rare
alleles identified minus the number of novel rare alleles
(n=56767 among cases, n=55742 among controls). The
same calculation was also performed for the variants
classified as novel and nonsynonymous.de novo Variant quality control
Due to the difficulty identifying de novo variants from
false positive genotype calls, we imposed strict quality
control criteria. These were based, in part, on the quality
control measures used in Neale et al. [24]. For a variant
to be considered de novo we required it to meet the fol-
lowing criteria: 1) more than 10 reads for the mother,
father and child carrying the de novo mutation; 2)
mother or father could have no more than 5% of the
total reads being from the non-referent allele; 3) if the
de novo variant in the child was heterozygous, the vari-
ant could have no more than 70% of the reads being
from the referent allele.Table 1 Demographic and phenotype information
Family member Age Asthma diagnosis Allergi
Mother 45 Yes Yes
Father 46 No Yes
Child 1 11 Yes Yes
Child 2 17 Yes Yes
Child 3 15 No No
Child 4 9 No No
1Child and parents were unable to provide the age of diagnosis of asthma, but the
between the ages of 1–2 years. The mother reported that this child had wheezing aResults
Two children reported a doctor’s diagnosis of asthma and
allergies and one of the two also reported taking albuterol
(up to 14 times per month) and a generic allergy medica-
tion (1–4 times per month) in the preceding 12 months.
The other asthmatic child was reported (per the mother)
as having wheeze and persistent cough during all seasons
of the first year of life. The two remaining children
reported not having a doctor’s diagnosis of asthma, no al-
lergies and no asthma or allergy medication use. The
mother reported having a doctor’s diagnosis of asthma
and allergies, and taking albuterol daily or almost daily
during the previous 12 months. The father reported not
having a doctor’s diagnosis of asthma, but reported having
allergies and taking a generic allergy medication 1–4 times
in one of the preceding 12 months. See Table 1 for demo-
graphic and phenotypic details.
Overall, we attained high coverage of the exome, with
four samples achieving >100 million 76 bp paired-end
reads and the other two with more than 52 and 89 million
reads (Table 2). For called variants, the average coverage
was more than 100X for all subjects and among variants
that passed all filters more than 110X (Table 2). It should
be noted that Child 3 had fewer reads and lower coverage,
however this only resulted in ~2% fewer called variants
within exons that passed our stringent quality control fil-
ters. There were 55,370 variants called that were variable
in one or more of the samples. After applying stringent
quality control filters to eliminate low quality variants,
38,103 remained. The depth of coverage (i.e. the number
of times an individual base was sequenced) of variants was
high in all samples, with average per-sample depth of
coverage of variants ranging from 92X to 210X among the
high quality variants (Table 2). Of these high quality var-
iants, the majority were within exons (66.3%), the 3’ un-
translated regions (12.8%), introns (9%), 5’ untranslated
regions (6%), or exons of non-coding RNAs (3.7%) (Table 3).
Less than 1% of all high quality variants were in regions not
considered to be within or around genes (Table 3).
Given our interest in functional, family-specific var-




15 Albuterol, Generic Allergy
NA None
NA None
mother reported the child being diagnosed with reactive airway disease
nd persistent cough during the first year of life.






















Mother 89,967,478 2,061,484 10,764,768 8,577,327 1,636,019 36,275 156.0 28,232 148.7
Father 107,937,586 2,297,044 12,181,833 10,863,150 1,863,721 36,650 187.3 28,007 183.0
Child 1 105,231,048 2,088,137 10,883,542 12,455,453 1,705,727 37,267 174.7 28,370 169.6
Child 2 129,947,192 2,401,685 11,122,401 15,054,214 2,012,381 37,457 213.4 28,413 210.4
Child 3 52,005,299 932,213 3,544,678 2,870,062 634,587 34,826 100.4 27,376 92.9
Child 4 118,061,614 2,832,204 15,671,206 13,849,071 2,369,338 36,946 195.4 28,374 190.7
Total Unique1 55,370 38,103
1Total number of unique variants across all six samples.
2Number of pairs of reads (reads from the opposite ends of the same DNA molecule) for which the corresponding read pair was identified.
3Number of reads for which the corresponding read pair was not identified.
4Number of reads that could not be mapped to the reference human genome.
5Number of read pairs that were the result of PCR duplicates.
6Number of unpaired reads that were the result of PCR duplicates.
7Total number of variants called by the Genome Analysis Toolkit (SNPs and indels).
8Average depth of coverage across all variants called for an individual sample.
9Number of variants that passed the quality control filters (see Alignment, Variant Identification and Filtering section above).
10Average depth of coverage across all variants that passed the quality control filters for an individual sample.
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then looked at variants where the two affected children
and the mother had at least one minor allele, but the un-
affected children and the father had at least one less
minor allele compared to the mother and affectedTable 3 Distribution of variant types





















1Variant types as annotated by ANNOVAR [Abbreviations: UTR3 = 3’
Untranslated region; UTR5 = 5’ Untranslated region; ncRNA = non-coding
RNA].
2Variants not considered to be within genes among all variants called (0.7%)
and variant that passed the stringent QC filters (0.6%).children. There were 14 variants that met these cri-
teria, however, four of these variants were identified in
the 1000 genomes project and were excluded leaving
ten variants for further consideration (Table 4). In all
cases, affected individuals were heterozygous and un-
affected individuals were homozygous wild-type. Based
on the functional prediction scores (two or more algo-
rithms indicate a high probability of functionality
(marked with an asterisk in Table 4), four variants in
four different genes were deemed functionally interest-
ing (PDE4DIP, CBLB, KALRN, GALNTL6). No muta-
tion was predicted to be fuctional by all programs, and
none by more than three of the five programs. The
isoleucine to leucine change in PDE4DIP was predicted
to be functional by Mutation Taster (high probability
of a disease causing site) and LRT (evidence of codon
constraint). The CBLB mutation of aspartic acid to ala-
nine was predicted to be functional by PhyloP (highly
conserved among 46 vertebrate species), Mutation
Taster and LRT. The leucine to phenylalanine muta-
tion in KALRN was supported by PhyloP and LRT,
whereas the isoleucine to valine mutation in GALNTL6
was supported by SIFT (high probability of a damaging
change) and PhyloP. Three of these genes (PDE4DIP,
CBLB, and KALRN) are of increased interest based on
either their function or previous work in asthma. All
three SNPs were re-genotyped using TaqMan and for
each SNP the mother and both affected children were
heterozygous, while the father and two unaffected
children were homozygous wild-type (Table 5). In
addition, we genotyped four SNPs that have been
reported to be associated with asthma, rs7216389 in
ORMDL3, rs11684634 in PDE11A, rs1544791 in
Table 4 Family-specific variants identified in mother and two affected children and variant annotations from
ANNOVAR
Functional prediction program
Gene Amino acid change1 Chr2 Pos3 SIFT4 PolyPhen25 PhyloP6 Mutation taster7 LRT8
PDE4DIP I303L 1 144930802 0.47 0.45 0.75 1.00* 0.95*
FCRL6 R123Q 1 159778799 0.14 0.28 0.02 0.01 0.00
AIM2 N194D 1 159035936 0.00 0.99* 0.16 0.08 0.69
ZBTB37 M396V 1 173854936 0.00 – – – –
IER5 E103K 1 181058345 0.07 0.07 0.94 0.02 0.91
CBLB D454A 3 105438937 0.37 0.78 0.99* 0.99* 0.99*
CCDC80 S95L 3 112358469 0.13 0.03 6.2E-4 0.04 6.0E-6
KALRN L1644F 3 124281690 0.00 0.83 0.99* 0.72 0.99*
GALNTL6 I160V 4 173269765 1.00* 0.00 0.99* 0.00 0.84
COMMD5 R38Q 8 146076611 0.47 0.03 0.10 0.06 0.94
1Amino acid changes are represented as the wild type amino acid, position of the amino acid in the polypeptide chain followed by the amino acid resulting from
the mutation. All amino acids are represented by the single letter amino acid code.
2Chr = Chromosome.
3Pos = chromosome position.
4SIFT, prediction of a change being damaging (>0.95) or tolerated. Values >0.95 are marked with an asterisk. For all five functional prediction programs, missing
values (−−) were not provided by ANNOVAR.
5PolyPhen2, prediction of a change being damaging (>0.85), possibly damaging (0.15-0.85) or benign (<0.15). Values >0.85 are marked with an asterisk.
6Phylop, prediction of a conserved (>0.95) or non-conserved site (<0.95) sites across species. Values >0.95 are marked with an asterisk.
7Mutation Taster, prediction of a disease-causing variant (1 – p-value). Values >0.95 are marked with an asterisk.
8LRT, likelihood ratio test for codon constraint. Values >0.95 are marked with an asterisk.
DeWan et al. BMC Medical Genetics 2012, 13:95 Page 6 of 9
http://www.biomedcentral.com/1471-2350/13/95PDE4D and rs2706347 in RAD50 (Table 5). We did
not observe the risk allele segregating with the affec-
tion status for any of these “common” asthma
variants.
To determine if the asthmatic children carried more
rare variants in asthma candidate genes than non-
asthmatic children, we queried the 251 asthma candidate
genes from our previous study [23] to determine the
number of variants each child in this family had across
this set of genes. This was done for all variants regard-
less of function or frequency, only variants classified as
novel (not observed in dbSNP), and only novel and non-
synonymous variants. While one of the affected children
had the most number of rare alleles across candidate
genes (n=427), one of the unaffected children had the
second highest number of rare alleles (n=422). However,
when we limited this to either novel variants or novel
and nonynonymous variants, the affected children had
more rare alleles than unaffected children in bothTable 5 Genotypes at exome sequence candidate SNPs and fo
Family member Asthma phenotype CBLB (G)1 KALRN (T)1 PDE
Mother Affected GT CT
Father Unaffected TT CC
Child 1 Affected GT CT
Child 2 Affected GT CT
Child 3 Unaffected TT CC
Child 4 Unaffected TT CC
1Minor or risk allele is in parentheses.categories (Table 6), but this difference did not reach
statistical significance for either novel (p=0.112) or novel
and nonsynonymous (p=0.097) when compared to the
total number of variants passing QC among the affected
and unaffected children. Despite the lack of statistical
significance the direction of the association indicated
that the number of rare variants increased risk among
both the novel (OR=1.964; 95%CI: 0.84-4.58) and novel
and nonsynonymous (OR=2.357; 95%CI: 0.83-6.69).
One advantage that we had sequencing an entire nu-
clear family was the ability to identify de novo variants,
variants identified in the children not observed in either
parent. We identified 279 de novo variants that were
present in one or more of the children, but not in the
parents that passed our initial QC. Overall these variants
had low coverage with an average of 13.5X and drastic-
ally higher than the < 1 event per subject observed in re-
cent studies [24,25]. When we imposed strict quality
control criteria (see Methods) to distinguish true positiveur additional asthma associated SNPs
4DIP (C)1 ORMDL3 (T)1 RAD50 (T)1 PDE11A (C)1 PDE4D (T)1
AC TT GT AA CC
AA CT GT AC CT
AC CT TT AC CT
AC CT TT AC CC
AA CT TT AC CT
AA CT GG AA CT













Child 1 Affected 415 8 6
Child 2 Affected 427 8 6
Child 3 Unaffected 396 3 1
Child 4 Unaffected 422 5 4
1Varants passing QC filters.
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three de novo variants in three subjects. However, it is
reasonable to assume that de novo events are likely not
to have been previously ovbserved. Therefore, we
restricted this to only variants not in dbSNP, leaving two
de novo variants (Table 7). These two variants had high
overall coverage with an average of 212X across the six
family members. These two variants were both nonsy-
nonymous mutations, the first in the gene DST in a
non-asthmatic child and the second in the gene MEF2A
in an asthmatic child.Discussion
We recruited one family in which the mother and two
children reported a doctor’s diagnosis of asthma, but the
father and two additional children had no doctor’s diag-
nosis of asthma. After subjecting each family member’s
genome to whole exome sequencing, we identified ten
novel, nonsynonymous variants that segregated perfectly
with asthma. Three of these variants had high probabil-
ity to result in deleterious protein coding changes by
two or more functional prediction algorithms and were
also plausible asthma candidate genes based on their
function or previous asthma association studies.
PDE4DIP, also known as myomegalin, is a golgi asso-
ciated protein that is found to interact with a member of
the phosphodiesterase superfamily of proteins, PDE4D,
in the sarcomeric structure of skeletal muscle [26]. It
has been shown to regulate cardiac contractility through
its activity by phosphorylating Cardiac Myosin Binding




Chr2 Position Gen3 Reads4 Gen3 R
exonic MEF2A nonsyn1 15 100252908 0/0 155,0 0/0 1
exonic DST nonsyn1 6 56485113 0/0 221,0 0/0 3
1Nonsynonymous.
2Chromosome.
3Genotype (0/0 = homozygous reference, 0/1 = heterozygous for the de novo varian
4Number of reads covering the variant site with the first number being the number
containing the de novo variant allele.While no studies have shown expression of PDE4DIP in
lung tissue, interest in this gene potentially playing a role
in asthma susceptibility stems from the fact that it inter-
acts with PDE4D. A GWAS identified an association
between childhood asthma and variants in PDE4D and
was replicated in several populations [3].
CBLB codes for the protein E3 ubiquitin ligase Cbl-b a
member of the Cbl family of proteins. Of particular
interest is its reported role in the regulation of the T cell
response through promotion of the clearance of the T-
cell receptor from the cell surface [28]. It has previously
been reported that a region of chromosome 7 containing
the T-cell receptor gamma (TCRγ) gene is associated
with asthma [29,30].
KALRN codes for the protein kalirin. Reduced levels of
kalirin have been associated with increased inducible ni-
tric oxide synthetase (iNOS) activity [31] and promoter
polymorphisms in the iNOS gene have been associated
with allergic asthma severity [32]. Evidence for an in-
volvement of KALRN is further supported by the finding
of a nominal association with a single-nucleotide poly-
morphism in KALRN in our previously published GWAS
of childhood asthma [16].
The focus of GWAS has been on identifying common
risk variants associated with disease. However, recent
large-scale sequencing studies suggest that the majority
of variation present in the genome is rare, and estimates
of frequency of novel variants are as high as 82% [33,34].
Given that the largest proportion of variants in the
genome may be novel, we chose to focus our attention
on variants not present in variant databases. It can be
argued that there may be rare, but not novel, variants
segregating with asthma in this family, but at least the
large consortium-based GWAS for asthma was likely
sufficiently powered to identify associations with even
these rare variants [2]. This allowed us to focus on var-
iants that might only be identified through the use of a
family-based design.
As expected, common risk variants in four asthma
candidate genes did not segregate with asthma in this
family. It appears as if one of the unaffected children
(child 4) had fewer risk alleles (n=2) than the other chil-
dren in this family (each had four or more), but it is noter Child 1 Child 2 Child 3 Child 4
eads4 Gen3 Reads4 Gen3 Reads4 Gen3 Reads4 Gen3 Reads4
87,0 0/1 73,65 0/0 223,0 0/0 76,0 0/0 196,3
33,1 0/0 248,0 0/0 326,0 0/0 145,0 0/1 168,122
t, 1/1 = homozygous de novo).
of reads containing the reference allele and the second the number of reads
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typic differences. However, we did observe that the
affected children had more rare alleles within a wider
array of asthma candidate genes compared to the un-
affected children. While this data is inconclusive, there
appears to be a trend of more rare variants in asthma
candidate genes among case children than control chil-
dren suggesting that a combination of rare variants
across multiple genes may be contributing to asthma
susceptibility. This is a hypothesis that will need to be
tested in a larger dataset.
One advantage of this family-based design is that we
had the ability to identify de novo mutation events that
could be potentially contributing to asthma susceptibil-
ity in the affected children or protecting against asthma
in the unaffected children. We identified two novel var-
iants in two genes, DST and MEF2A, that had high
coverage and could potentially be risk, MEF2A, or pro-
tective, DST, asthma variants. Both of these variants
were nonsynonymous variants, but neither were in
genes previously associated with asthma or had an ob-
vious function relationship with asthma. MEF2A codes
for a DNA-binding transcription factor and is primarily
found in proliferating smooth muscle cells in humans
[35]. Mutations in MEF2A have been associated with
with coronary artery disease (CAD) [36,37], however,
further evidence suggests that this is not a common
cause of CAD among whites [38]. DST codes for the
protein, dystonin, a member of the plankin family of
proteins, whose members differentially express splice
variants involved in the cytoskeletal needs of various
specialized cells [39]. A homozygous single base pair
deletion in DST was identified as the causal mutation
in a family segregating a lethal form of heredity sensory
autonomic neuropathy (HSAN) [40].
While many more families will be needed to demon-
strate the involvement of any of these genes in asthma,
this is the first report of a comprehensive examination
of exonic variants within a family segregating asthma
and one of the first to describe this for a common,
non-Mendelian disease. We chose to focus here on
family-specific variants, but asthma development is
likely influenced by both family-specific variants in
addition to more common asthma susceptibility var-
iants. Future studies will need to focus on identifying
family-specific variants across families that are all either
within the same gene or within genes in the same gen-
etic pathway. Finally, these family-specific variants will
need to be analyzed within the context of common
asthma susceptibility variants, the majority of which
are non-exonic, to yield a more comprehensive view of
genetic contributors to asthma across a range of effect
sizes. Whole-genome sequencing will enable such fu-
ture work.Conclusions
This is the first report applying exome sequencing to
identify asthma susceptibility variants. Despite having
sequenced only one family segregating asthma, we iden-
tified several potentially functional variants in three
interesting asthma candidate genes, PDE4DIP, CBLB and
KALRN. This will provide the basis for future work in
which more families will be sequenced to identify var-
iants across families that cluster within genes.
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